News articles about Petmed Express (NASDAQ:PETS) have been trending somewhat positive on Monday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Petmed Express earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.1480542395111 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Investing Lessons From My Hate Mail – Investorplace.com (investorplace.com)
- PetMed Express, Inc. (PETS) Ex-Dividend Date Scheduled for February 02, 2018 – Nasdaq (nasdaq.com)
- Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q4 (finance.yahoo.com)
- Ex-Dividend Alert: PetMed Express Raised its Dividend by 25%; Will Trade Ex-Dividend on February 02, 2018 (finance.yahoo.com)
- Wired News – Aradigm Announced Rejection of Linhaliq(TM)’s New Drug Application by FDA (finance.yahoo.com)
Petmed Express (NASDAQ:PETS) opened at $43.27 on Monday. The firm has a market capitalization of $891.41, a PE ratio of 25.60, a PEG ratio of 2.55 and a beta of 0.95. Petmed Express has a one year low of $19.21 and a one year high of $57.80.
Petmed Express (NASDAQ:PETS) last released its quarterly earnings data on Monday, January 22nd. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.11. The firm had revenue of $60.10 million during the quarter, compared to analyst estimates of $56.76 million. Petmed Express had a return on equity of 34.04% and a net margin of 12.84%. The business’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.24 earnings per share. equities analysts predict that Petmed Express will post 1.7 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 16th. Stockholders of record on Monday, February 5th will be paid a $0.25 dividend. This is a positive change from Petmed Express’s previous quarterly dividend of $0.20. The ex-dividend date is Friday, February 2nd. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.31%. Petmed Express’s dividend payout ratio is 59.17%.
Several analysts have issued reports on PETS shares. Noble Financial reissued a “hold” rating on shares of Petmed Express in a report on Friday, October 27th. Zacks Investment Research raised Petmed Express from a “sell” rating to a “hold” rating and set a $50.00 price target for the company in a report on Friday, October 20th. BidaskClub lowered Petmed Express from a “strong-buy” rating to a “buy” rating in a report on Friday, January 19th. Finally, Northcoast Research set a $58.00 price target on Petmed Express and gave the company a “buy” rating in a report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $42.80.
In other news, Director Gian Fulgoni sold 20,000 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $44.38, for a total value of $887,600.00. Following the completion of the transaction, the director now owns 55,900 shares of the company’s stock, valued at $2,480,842. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Menderes Akdag sold 30,000 shares of the company’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $51.00, for a total value of $1,530,000.00. Following the completion of the transaction, the chief executive officer now directly owns 490,000 shares of the company’s stock, valued at approximately $24,990,000. The disclosure for this sale can be found here. In the last ninety days, insiders sold 65,000 shares of company stock valued at $3,229,500. Corporate insiders own 4.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Petmed Express (PETS) Earns Daily News Sentiment Rating of 0.24” was originally reported by Stock Observer and is the property of of Stock Observer. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.thestockobserver.com/2018/02/05/petmed-express-pets-earns-daily-news-sentiment-rating-of-0-24.html.
About Petmed Express
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.